Immune booster before chemo shows promise for tough breast cancer
NCT ID NCT02957968
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these drugs, then proceed to usual chemo. The goal is to see if this approach increases immune cell activity in the tumor, potentially improving treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
-
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can radiation replace surgery for cancer spread to lymph nodes?
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- Could a common cholesterol drug boost breast cancer treatment?
- New drug cocktail aims to outsmart resistant breast cancer
- Can a smartphone app help latina breast cancer patients beat the odds?